ClinicalTrials.Veeva

Menu
C

Canberra Hospital | Gastroenterology Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Bendamustine
Gemcitabine
Empagliflozin
prednisone
LUM-201
Pembrolizumab
BI 1015550
cyclophosphamide
Carboplatin
vincristine sulfate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

22 of 64 total trials

A Follow-up Study to Test Long-term Treatment With BI 1015550 in People With Pulmonary Fibrosis Who Took Part in a Previous Study With BI 1015550 (FIBRONEER™-ON)

This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have c...

Enrolling
Progressive Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Drug: BI 1015550

This is a multi-national trial. The trial aims to study the long-term safety of LUM-201 in subjects with Idiopathic Pediatric Growth Hormone Deficien...

Invitation-only
Growth Hormone Deficiency
Drug: LUM-201

Study consists of two parts, a part 1 dose escalation and a part 2 cohort expansion in combination with dexamethasone and carfilzomib intravenously a...

Enrolling
Relapsed/Refractory Multiple Myeloma
Drug: Carfilzomib
Drug: Dexamethasone

he purpose of the study is to evaluate the efficacy, safety, and tolerability BGB-3111 plus obinutuzumab versus obinutuzumab alone in participants wi...

Active, not recruiting
Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
Drug: Zanubrutinib
Drug: Obinutuzumab

The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiov...

Active, not recruiting
Obesity
Cardiovascular Diseases
Drug: Retatrutide
Drug: Placebo

This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic...

Active, not recruiting
Lung Diseases, Interstitial
Drug: BI 1015550
Drug: Placebo

This study is open to adults 40 years or older with idiopathic pulmonary fibrosis (IPF). People can join the study if they are not on any treatment f...

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: Placebo matching BI 1819479
Drug: BI 1819479

This study is a prospective, multi-center, pivotal trial to study the safety and efficacy of the WiSE-CRT System for Cardiac Re-synchronization Thera...

Active, not recruiting
Heart Failure
Device: WiSE System

Patients with pleural mesothelioma (PM) that cannot be surgically removed will receive standard chemotherapy (cisplatin or carboplatin and pemetrexed...

Active, not recruiting
Malignant Pleural Mesothelioma
Pleural Mesothelioma
Drug: Standard Chemotherapy
Drug: Durvalumab

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults wi...

Active, not recruiting
Coronary Heart Disease (CHD)
Drug: Evolocumab
Drug: Placebo

Phase 3, randomized, multicentre study to evaluate the efficacy and safety of dostarlimab versus carboplatin-paclitaxel in patients with MMR deficien...

Enrolling
Endometrial Cancer
Drug: Carboplatin-Paclitaxel
Drug: Dostarlimab

The purpose of this study is to find out whether a new drug, Ipatasertib, can slow the growth of advanced breast cancer when added to standard therap...

Active, not recruiting
Breast Cancer
Drug: Ipatasertib
Other: Placebo

The LEADR study is designed to assess the safety and efficacy of the Next Generation ICD lead.The LEADR LBBAP study is being conducted under the exis...

Enrolling
Tachyarrhythmia
Device: Defibrillation (RV Implant)
Device: Defibrillation (LBBAP Implant)

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (C...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Olpasiran
Drug: Placebo

The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to sunitinib or pazopanib in participant...

Active, not recruiting
Renal Cell Carcinoma (RCC)
Drug: Pazopanib
Drug: Epacadostat

This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator's...

Active, not recruiting
Primary Peritoneal Cancer
Fallopian Tube Cancer
Biological: Pembrolizumab
Drug: Gemcitabine

The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The pha...

Enrolling
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Drug: Low-intensity chemotherapy regimen
Drug: Blinatumomab

This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreat...

Active, not recruiting
Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
Drug: zanubrutinib
Drug: rituximab

This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who have previously received treatment with...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Idelalisib
Drug: Bendamustine

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Chronic Kidney Disease (CKD)
Drug: Retatrutide
Drug: Placebo

Trial sponsors

Boehringer Ingelheim logo
Amgen logo
BeiGene logo
C
Lilly logo
Pfizer logo
Celgene logo
E
Gilead Sciences logo
L

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems